News

Treatment for opioid use disorder is limited by there not being enough people that offer medications for opioid use disorder,” said Brian Hurley, MD, MBA, president-elect of the American Society of Addiction Medicine (ASAM). “Removal of the X waiver opens up the capability of prescribing to a much broader group of clinicians.

What happens when a patient who is prescribed buprenorphine undergoes surgery? Experts say they should continue the medication, predominantly prescribed for opioid use disorder, throughout the entire perioperative period. It doesn’t need to be stopped, Lynn Kohan, MD, the medical director of the Pain Management Center told Pain Medicine News.

Bridge Therapeutics is delighted to announce that it achieved a Bronze Award on the Pepperdine Graziadio Business School’s fifth annual Most Fundable Companies® List. Bridge Therapeutics competed against over 4,000 of early-stage US companies to be named one of 16 finalists.

Lynn Fosse, Senior Editor of CEOCFO Magazine sits down with Tim Peara, President of Bridge Therapeutics to discuss commercialization and development of its opioid addiction and chronic pain drugs.

New York, New York – August 29, 2022:  Bridge Therapeutics, a developmental stage pharmaceutical company, today reported continued progress towards Phase 3 FDA approval of BT 219, a patented combination of Buprenorphine and Naloxone for Opioid Use Disorder (OUD). Simultaneously, Bridge reported that Darren Prince, an internationally recognized speaker and advisor on matters of addiction and mental health recovery…

Bridge reported that Darren Prince, an internationally recognized speaker and advisor on matters of addiction and mental health recovery has joined Bridge’s commercial advisory board. He abused opioids for more than 20 years before breaking his addiction, and then went on to help many other people, in and out of the entertainment industry, struggling with opiate…

Bridge Therapeutics announced today that they were selected as one of the Top 100 startups to compete and participate in the 9th Annual Startup of the Year Summit. “The Startup of the Year competition is a great way to showcase our innovative approach to treating opioid addiction and chronic pain,” says Dr. Greg Sullivan, founder and Chief Science Officer at Bridge Therapeutics.

Treatment advocates are hailing those new laws as well as several recent changes to federal regulation designed to reduce the stigma around addiction, close gaps in treatment and expand access to critical medications, including naloxone and buprenorphine, a highly effective intervention for opioid addiction.

In a series of presentations at the 2021 virtual meeting of the North American Neuromodulation Society, Lynn R. Webster, MD, and his colleagues concluded that the novel agent was not associated with significantly decreased respiratory drive and also may have a lower risk for abuse potential than oxycodone.

In a Jan. 26 statement, the American Society of Addiction Medicine, the National Council for Behavioral Health and a handful of other addiction advocacy groups urged Congress to eliminate the training requirement as quickly as possible. “As clinicians and advocates on the frontlines of the addiction and overdose crisis, we call on congressional leaders to…